Hostname: page-component-cb9f654ff-5kfdg Total loading time: 0 Render date: 2025-08-29T13:11:22.025Z Has data issue: false hasContentIssue false
  • English
  • Français

Development of new antidepressants

Published online by Cambridge University Press:  02 January 2018

Eleni Palazidou
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The development of the first effective antidepressants in the late 1950s marked a turning point in the treatment of depressive illness. In 1957 the monoamine oxidase inhibitor (MAOI) iproniazid was discovered by chance, while searching for new antituberculous drugs. One year later the tricyclic antidepressant (TCA) imipramine was introduced, having been developed originally as an antipsychotic. A number of other drugs were subsequently added to these two groups of antidepressants, which dominated the field for the next three decades.

Information

Type
Research Article
Information
Advances in Psychiatric Treatment , Volume 3 , Issue 1 , January 1997 , pp. 46 - 51
Copyright
Copyright © The Royal College of Psychiatrists 1997 

References

Anderson, I. (1997) Lessons to be learnt from meta-analyses of newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 57–62.Google Scholar
Boyer, W. F. & Feigner, J. P. (1993) The financial implications of starting treatment with a selective serotonin reuptake inhibitor or tricyclic antidepressant in drug-naive depressed patients. In Health Economics of Depression (eds Jönsson, B. & Rosenbaum, J.) pp. 65–75. Chichester: Wiley.Google Scholar
Crewe, H. K., Lennard, M. S., Tucker, G. T. et al (1992) The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6(CYP2D6) activity in human liver microsomes. British Journal of Clinical Pharmacology, 34, 262–265.CrossRefGoogle ScholarPubMed
Emrich, H. M., Berger, M., Riemann, D. et al (1987) Serotonin reuptake inhibition vs. norepinephrine reuptake inhibition: A double-blind differential-therapeutic study with fluvoxamine and oxaprotiline in endogenous and neurotic depressives. Pharmacopsychiatry, 20, 60–63.Google Scholar
Henry, J. A. (1997) Toxicity of newer versus older antidepressants. Advances in Psychiatric Treatment, 3, 40–44.CrossRefGoogle Scholar
Leonard, B. E. (1993) Comparative pharmacology of new antidepressants. Journal of Clinical Psychiatry, 54 (suppl. 8), 3–15.Google ScholarPubMed
Montgomery, S. (1982) The non-selective effects of selective antidepressants. Advances in Biochemistry and Pharmacology, 31, 49–56.Google Scholar
Preskorn, S. H. (1993) Sudden death and tricyclic antidepressants (TCAs): A rare adverse effect linked to high plasma levels. Nordic Journal of Psychiatry, 47 (suppl. 30), 49–55.CrossRefGoogle Scholar
Preskorn, S. H. & Jerkovich, G. S. (1990) Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors and role of therapeutic drug monitoring. Journal of Clinical Pharmacology, 10, 88–95.Google Scholar
Sulser, F., Vetulani, J. & Mobley, P. L. (1978) Mode of action of antidepressant drugs. Biochemical Pharmacology, 27, 257–261.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.